Cost of Revenue: Key Insights for Pfizer Inc. and Amgen Inc.

Cost of Revenue Trends: Pfizer Inc. vs. Amgen Inc.

In the ever-evolving pharmaceutical industry, understanding cost structures is crucial. Over the past decade, Pfizer Inc. and Amgen Inc. have shown distinct trends in their cost of revenue. From 2014 to 2023, Pfizer's cost of revenue surged by approximately 210%, peaking in 2022. This reflects their aggressive expansion and increased production, especially during the pandemic years. In contrast, Amgen's cost of revenue grew by about 90% over the same period, indicating a more stable growth trajectory. Notably, 2021 marked a significant spike for Pfizer, with costs tripling compared to 2020, likely due to their COVID-19 vaccine production. Meanwhile, Amgen's costs remained relatively steady, with a notable increase in 2023. These insights highlight the strategic differences between the two giants, with Pfizer focusing on rapid scaling and Amgen maintaining steady growth.